UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
| (Check
one): |
☐ |
Form
10-K |
☐ |
Form
20-F |
☐ |
Form
11-K |
☒ |
Form
10-Q |
☐ |
Form
10-D |
☐ |
Form
N-SAR |
☐ |
Form
N-CSR |
| |
For
Period Ended: |
September
30, 2026 |
| |
|
|
| |
☐ Transition
Report on Form 10-K |
| |
|
| |
☐ Transition
Report on Form 20-F |
| |
|
| |
☐ Transition
Report on Form 11-K |
| |
|
| |
☐ Transition
Report on Form 10-Q |
| |
|
| |
☐
Transition Report on Form N-SAR |
| |
|
| |
For
the Transition Period Ended: |
|
Read
Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
|
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I — REGISTRANT INFORMATION
| SHUTTLE
PHARMACEUTICALS HOLDINGS, INC. |
| Full
Name of Registrant |
| |
| |
| Former
Name if Applicable |
| |
| 401
PROFESSIONAL DRIVE SUITE 260 |
| Address
of Principal Executive Office (Street and Number) |
| |
| GAITHERSBURG,
MD 20879 |
| City,
State and Zip Code |
PART
II — RULES 12b-25 (b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
| |
(a) |
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
| |
|
|
| ☒ |
(b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the
fifth calendar day following the prescribed due date; and |
| |
|
|
| |
(c) |
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III — NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report portion thereof, could not
be filed within the prescribed time period.
The
Registrant has been unable, without unreasonable effort or expense, to timely compile all information for the disclosures required to
be included in its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2026 (the “Quarterly Report”), primarily as a result of the change in control analysis described further below in Part IV(3). The
Registrant expects to file the Quarterly Report no later than the fifth calendar day following the prescribed filing date.
| SEC
1344 (04-09) |
|
Persons
who are to respond to the collection of information contained in this form are not required to respond unless the form displays a
currently valid OMB control number. |
(Attach
extra Sheets if Needed)
PART
IV — OTHER INFORMATION
| (1) |
Name
and telephone number of person to contact in regard to this notification |
| |
|
| |
Chris
Cooper
|
|
(240)
|
|
403-4212
|
| |
(Name) |
|
(Area
Code) |
|
(Telephone
Number) |
| (2) |
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If answer is no, identify report(s). |
| |
|
|
Yes
☒ No ☐ |
| |
|
| (3) |
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof? |
| |
|
|
Yes
☒ No ☐ |
| |
|
| |
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made. |
| |
|
| |
As
part of the Registrant’s review and preparation of its quarterly financial statements
for the period ended September 30, 2026, management of the Registrant, in consultation with
the Registrant’s advisors, determined that a change in control of the Registrant occurred
on September 9, 2026 in connection with the conversion of certain of its issued and outstanding
shares of Series B-1 Preferred Stock (the “B-1 Preferred Stock”) into shares
(the “UDC Conversion Shares”) of the Registrant’s common stock, par value
$0.00001 per share (“Common Stock”). As of September 14, 2026, the former stockholders
(the “Former UDC Stockholders”) of United Dogecoin Inc., a Delaware corporation
(“UDC”), beneficially owned an aggregate of approximately 2,554,982 shares
of Common Stock, representing approximately 53.6% of the Registrant’s outstanding
Common Stock, after giving effect to the 4.99% beneficial ownership limitations set forth
in the terms of the B-1 Preferred Stock and certain pre-funded warrants also held by the
Former UDC Stockholders.
As
a result of the change in control described above, the Registrant has determined to account
for the issuance of the UDC Conversion Shares as a reverse asset acquisition, with
UDC as the accounting acquirer. This determination is consistent with the Registrant’s
prior conclusion that UDC did not obtain control of the Registrant upon the closing of the
Registrant’s previously disclosed merger with UDC, because control passed only upon
the issuance of the UDC Conversion Shares. Accordingly, the historical financial information,
including the results of operations and financial statements, to be included in the Quarterly
Report will be that of UDC, rather than that of the Registrant prior to the issuance of the
UDC Conversion Shares. The Registrant therefore anticipates that its results of operations
reflected in the Quarterly Report will differ significantly from the results previously reported
by the Registrant for the corresponding period of the prior fiscal year.
|
SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: November 17, 2026 |
By: |
/s/
Chris Cooper |
| |
|
|
Chris
Cooper |
| |
|
|
Co-CEO |